Plain-English translation of NCT03994471 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing XyloCore, a new type of fluid used in peritoneal dialysis (a home-based kidney treatment), to see if it works as well as the standard glucose-based dialysis solutions most people currently use. The key difference is that XyloCore is designed to help your body filter waste without relying as heavily on glucose, which may reduce some side effects. Researchers want to know if this medication can keep you healthy while potentially offering additional benefits.
People on peritoneal dialysis use glucose-containing solutions to help remove waste and excess fluid from their blood, but the glucose can be absorbed into the body and cause weight gain, high blood sugar, and other metabolic problems. This medication was developed as an alternative that may be gentler on your body while still doing the same job of keeping you healthy.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either continue your current standard dialysis solution or switch to the new XyloCore medication. Either way, you will continue your regular dialysis routine at home, using 1 to 3 daily exchange bags plus a special overnight bag. Your doctor will monitor your health with regular visits and blood tests to make sure the treatment is working well and keeping you safe throughout the study.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Denmark
Germany
Italy